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Aims: Some studies suggested that abnormal diastolic dysfunction was an
early manifestation of Hypertrophic Cardiomyopathy (HCM) and that Tissue
Doppler Imaging (TDI) was able to correctly identify mutation carriers before
the development of hypertrophy. Data are however limited and still controver-
sial. We therefore performed a systematic analysis of Echocardiography, TDI
and ECG in familial HCM to identify predictive parameters for genetic status.
Methods and Results: We recruited 120 adults spread out in three groups:
HCM patients with hypertrophy (LVH+, n=48), mutation carriers without
hypertrophy (LVH-/G+, n=24), normal control subjects (n=48). Several
parameters were significantly different in G+/LVH- as compared to controls,
including septal Ea peak velocity. Multivariate logistic regression identified
three Echographic/TDI independent predictors for genetic status in LVH-free
subjects: the inter-ventricular/left posterior wall (IVS/LPW) ratio, the relative
wall thickness (RWT) and the septal E/Ea ratio. An Echo/TDI score deter-
mined after ROC analysis, showed 67% sensitivity and 96% specificity for the
identification of mutation carriers. In comparison, sensitivity and specificity of
septal Ea peak velocity (<13 cm/s) were 63% and 69% respectively. Major
ECG abnormalities were not correlated with the Echo/TDI score and sensi-
tivity of ECG was only 33%.
Conclusion: Although DTI velocities alone were not reliable enough to
identify LVH-free mutation carriers in HCM, a new Echo/TDI score can
achieve preclinical diagnosis with high accuracy. Abnormal LV remodeling,
and not only functional abnormalities, might be an early manifestation of
HCM in human. 
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Objectives: ECMO is an effective technique to provide emergency
mechanical circulatory assistance for patients with cardiogenic shock refrac-
tory to conventional medical therapies. For patients outside our institution we
create a Heliported Remote Cardiac Assist unit to implant the ECMO. Our
study was undertaken to evaluate the feasibility of the procedure and the
results of our experience.
Methods: Between March 2006 and June 2008 38 consecutive patients in
acute cardiogenic shock were implanted with percutaneous ECMO by our heli-
ported team.
Results: Mean distance from our ICU was 42 miles (1-143). Maximal time
limit between phone call and implantation was 90 min. Mean LVEF evaluated
by TTE was 19 ± 5%. Indications were fulminant myocarditis, pharmacologic
suicide attempt, acute myocardial infarction, post-partum cardiopathy, end-
stage dilated cardiomyopathy. They received a percutaneous veno-arterial fem-
oral ECMO with immediate reperfusion of the limb. Seventeen patients (45%)
were successfully weaned from ECMO after 9.4 ± 8.7 days. Four patients
(11%) were transplanted. One patient (3%) was switched to a left ventricular
assist device and successfully transplanted. Twenty-one patients (55%) sur-
vived to hospital discharge.
Conclusions: The Heliported Cardiac Remote Assist unit allowed the
emergent implant of ECMO support and could rescue 55% of otherwise lethal
cardiogenic shock patients in remote institutions.
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Background: Left ventricular non compaction (LVNC) is a recently iden-
tified cardiomyopathy, characterized by an excessively prominent trabecular
meshwork and deep intertrabecular recesses. Some genes have been described
as responsible for LVNC, including TAZ and LDB3, but the precise preva-
lence of these genes and the impact of mutation screening in clinical practice
are poorly understood.
Objective: To assess the prevalence of mutations in TAZ (tafazzin, Xq28)
and LDB3 (LIM domain-binding3/Cypher/ZASP, 10q23.2) genes in a large
cohort of patients with LVNC, whatever the familial context.
Methods: DNA was extracted from a population of 59 consecutive patients
with a definitive diagnosis of LVNC (Echo core lab), from the French registry
of LVNC. Direct sequencing of exons and intron-exon boundaries was per-
formed with ABI Prism 3100 Genetic Analyzer (Applied Biosystems). The
suspected mutations were tested in a control population (>240 chromosomes);
segregation within the families were analysed when available; evolutive con-
servation among various species were analysed by multiple alignement.
Results: We identified two new missense mutations in the TAZ gene
(Phe128Ser and Met155Val) in two index male patients. No mutation was
observed in the LDB3 gene, but two new genetic polymorphisms. The preva-
lence of TAZ mutations was 3% (2/59) and 0% for LDB3.
Conclusion: Mutations in TAZ gene were not unfrequent in LVNC whereas
no mutation was observed in LDB3 gene. These findings may have impact for
LVNC mutation screening strategy in clinical practice, and also for genetic
counselling as TAZ mutations are associated with X-linked inheritance.
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Background: The recent European Guidelines for the treatment of CHF
2008 underlined that the majority of patient with CHF and COPD can safely
tolerate β-blocker therapy.
Aims: The IMPACT-RECO program III analysed the impact of NYHA
class and of comorbidities on therapeutic management of French outpatients
with stable CHF and left ventricular ejection fraction (LVEF) < 40%.
Methods: This survey was carried out from March 2007 to December 2007
among randomly selected French private cardiologists. 1574 patients with CHF
and LVEF < 40% were included. Key demographics including comorbidities
such as asthma and COPD, as well as ongoing medical treatment of CHF were
collected. Physicians were asked about reasons for not prescribing β-blockers.
Results: Mean age was 71 ± 11 years, 75% of the patients were men, 34%
were in NYHA class III-IV, 54% had coronary artery disease, 30% atrial
fibrillation and the mean LVEF was 34 ± 7%. 78.3% of the patients received
a β-blocker, and asthma or BPCO were reported in 13.7%. 341 patients were
